Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sagimet Biosciences Inc.

2.39
+0.18008.14%
Post-market: 2.460.0687+2.87%17:41 EDT
Volume:1.49M
Turnover:3.69M
Market Cap:76.95M
PE:-1.64
High:2.67
Open:2.29
Low:2.29
Close:2.21
Loading ...

ProQR Appoints Dennis Hom as CFO, Cristina Lopez as CMO

MT Newswires Live
·
14 Apr

Sagimet Biosciences: Promising Future with Phase 3 MASH Trials and Strong Financial Position

TIPRANKS
·
14 Mar

Sagimet Biosciences Price Target Announced at $32.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Mar

Sagimet Biosciences Faces AI Integration Challenges: Security, Compliance, and Cost Risks Loom

TIPRANKS
·
13 Mar

Sagimet Biosciences Advances MASH Treatment with New Trials

TIPRANKS
·
13 Mar

Sagimet Biosciences Price Target Maintained With a $32.00/Share by HC Wainwright & Co.

Dow Jones
·
12 Mar

Sagimet Biosciences’ Strategic Expansion into Acne Treatment with Promising FASN Inhibitor TVB-3567

TIPRANKS
·
12 Mar

Sagimet Reports Acne Drug Candidate Cleared for Clinical Trials

MT Newswires Live
·
11 Mar

Sagimet Biosciences receives FDA nod to begin testing its therapy for acne

Reuters
·
11 Mar

Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne

GlobeNewswire
·
11 Mar

Is Sagimet Biosciences Inc. (SGMT) the Best Get Rich Quick Stock to Invest In?

Insider Monkey
·
25 Feb

BRIEF-Sagimet Biosciences Announces Oral Presentation At The Mash Pathogenesis And Therapeutic Approaches Keystone Symposium

Reuters
·
19 Feb

Sagimet Biosciences Announces Oral Presentation at the Mash Pathogenesis and Therapeutic Approaches Keystone Symposium

THOMSON REUTERS
·
19 Feb

Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium

GlobeNewswire
·
19 Feb

Buy Recommendation for Sagimet Biosciences: Denifanstat’s Unique Profile and Undervaluation Offer Compelling Investment Opportunity

TIPRANKS
·
04 Feb

BUZZ-JonesTrading starts coverage on drug developer Sagimet with 'buy' rating

Reuters
·
27 Jan

Sagimet Biosciences Inc : Jonestrading Initiates Coverage With Buy Rating; Price Target $42

THOMSON REUTERS
·
27 Jan

Sagimet Biosciences initiated with a Buy at JonesResearch

TIPRANKS
·
27 Jan

With 43% stake, Sagimet Biosciences Inc. (NASDAQ:SGMT) seems to have captured institutional investors' interest

Simply Wall St.
·
20 Jan

Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Sagimet Biosciences, Inc. Class A (SGMT)

TIPRANKS
·
13 Jan